Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
Market Cap | 544.313 Million | Shares Outstanding | 342.335 Million | Avg 30-day Volume | 9.832 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.56 |
Price to Revenue | 39.2273 | Debt to Equity | 0.8233 | EBITDA | -223.775 Million |
Price to Book Value | 9.4976 | Operating Margin | -611.509 | Enterprise Value | 1.347 Billion |
Current Ratio | 0.894 | EPS Growth | 0.447 | Quick Ratio | 0.746 |
1 Yr BETA | 2.0165 | 52-week High/Low | 11.07 / 1.15 | Profit Margin | -786.3002 |
Operating Cash Flow Growth | 7.7805 | Altman Z-Score | -1.5388 | Free Cash Flow to Firm | -143.744 Million |
Earnings Report | 2022-08-05 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
CZEREPAK ELIZABETH EVP & CHIEF FINANCIAL OFFICER |
|
350,000 | 2022-05-18 | 3 |
|
0 | 2022-05-18 | 2 | |
|
0 | 2021-12-27 | 4 | |
JI HENRY SEE REMARKS |
|
4,367,500 | 2021-09-29 | 2 |
|
235,000 | 2021-09-03 | 2 | |
|
250,000 | 2021-08-30 | 1 | |
|
250,000 | 2021-08-30 | 1 | |
|
250,000 | 2021-08-30 | 1 | |
|
250,000 | 2021-08-30 | 1 | |
ASGHAR NAJJAM CHIEF FINANCIAL OFFICER |
|
156,974 | 2021-03-16 | 0 |
|
0 | 2020-06-15 | 0 | |
SHAO JIONG CHIEF FINANCIAL OFFICER |
|
0 | 2020-06-15 | 0 |
ZELDIS JEROME B SEE REMARKS |
|
0 | 2018-11-26 | 0 |
ALLY BRIDGE GROUP CAPITAL PARTNERS II, L.P. ALLY BRIDGE GROUP INNOVATION CAPITAL PARTNERS III, L.P. |
|
No longer subject to file | 2018-09-12 | 0 |
NG GEORGE K SEE REMARKS |
|
407,935 | 2018-02-28 | 0 |
FERRIGNO DEAN CHIEF ACCOUNTING OFFICER |
|
245 | 2018-02-28 | 0 |
|
8,617,513 | 2018-01-23 | 0 | |
|
0 | 2017-09-15 | 0 | |
ALLY BRIDGE GROUP CAPITAL PARTNERS II, L.P. ALLY BRIDGE LB HEALTHCARE MASTER FUND LTD |
|
9,537,940 | 2017-04-19 | 0 |
SU JEFFREY EXECUTIVE VP AND COO |
|
13,000 | 2017-02-03 | 0 |
HERDE KEVIN EXECUTIVE VP AND CFO |
|
7,000 | 2017-02-03 | 0 |
TOLEDANO MIRANDA JAYNE EVP-CORPORATE DEVELOPMENT |
|
0 | 2016-09-16 | 0 |
|
0 | 2016-07-11 | 0 | |
|
0 | 2016-07-11 | 0 | |
|
No longer subject to file | 2016-07-07 | 0 | |
|
8,061,999 | 2015-12-31 | 0 | |
|
8,061,999 | 2015-12-09 | 0 | |
UY GEORGE SEE REMARKS |
|
201,735 | 2015-09-18 | 0 |
|
7,188,061 | 2015-07-24 | 0 | |
MIAO ZHENWEI SVP, HEAD OF ADC DEVELOPMENT |
|
559,390 | 2015-05-21 | 0 |
DURAND MARK EVP & CFO |
|
0 | 2015-04-29 | 0 |
VINCENT RICHARD G SEE REMARKS |
|
0 | 2014-10-07 | 0 |
ROYAL MIKE SEE REMARKS |
|
0 | 2014-06-27 | 0 |
|
18,829,503 | 2011-04-15 | 0 | |
|
2,231,719 | 2011-04-15 | 0 | |
|
0 | 2011-04-15 | 0 | |
|
917,930 | 2010-12-21 | 0 | |
|
25,484,329 | 2010-11-29 | 0 | |
SCHUH ANTONIUS CHAIRMAN AND CEO |
|
25,484,329 | 2010-02-16 | 0 |
MOLSBERGEN MARTINA VP, BUSINESS DEVELOPMENT |
|
0 | 2010-02-05 | 0 |
RODI CHARLES P VP, RESEARCH & DEVELOPMENT |
|
0 | 2010-02-05 | 0 |
|
59,015,257 | 2009-09-21 | 0 | |
|
669,516 | 2009-09-21 | 0 | |
|
111,586 | 2009-09-21 | 0 | |
STEIN RONALD M |
|
1,693,472 | 2008-07-07 | 0 |
|
No longer subject to file | 2008-07-07 | 0 | |
|
785,925 | 2008-07-07 | 0 | |
|
41,086,194 | 2008-07-07 | 0 | |
SILVER NOAH M VP, SECRETARY AND TREASURER |
|
4,054,666 | 2008-07-07 | 0 |
|
No longer subject to file | 2008-07-07 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-20 17:14:46 -0400 | 2022-05-18 | A | 350,000 | a | 350,000 | direct | ||||||||||
2022-05-20 17:11:29 -0400 | 2022-05-18 | A | 100,000 | a | 100,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 22:15:04 UTC | -0.4637 | 1.2837 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 21:45:03 UTC | -0.4626 | 1.2826 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 21:15:04 UTC | -0.4626 | 1.2826 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 20:45:03 UTC | -0.4652 | 1.2852 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 20:15:04 UTC | -0.4652 | 1.2852 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 19:45:04 UTC | -0.4652 | 1.2852 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 19:15:03 UTC | -0.4652 | 1.2852 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 18:45:03 UTC | -0.5418 | 1.3618 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 18:15:03 UTC | -0.5418 | 1.3618 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 17:45:03 UTC | -0.681 | 1.501 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 17:15:03 UTC | -0.681 | 1.501 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 16:45:03 UTC | -0.6796 | 1.4996 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 16:15:03 UTC | -0.6796 | 1.4996 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 15:45:04 UTC | -0.6796 | 1.4996 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 15:15:03 UTC | -0.6796 | 1.4996 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 14:45:03 UTC | -0.1758 | 0.9958 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 14:15:03 UTC | -0.1758 | 0.9958 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 13:45:03 UTC | -0.1758 | 0.9958 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 13:15:04 UTC | -0.1758 | 0.9958 | 0 |
SORRENTO THERAPEUTICS INC SRNE | 2022-05-23 12:45:03 UTC | -0.1758 | 0.9958 | 0 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | SRNE | -107200.0 shares, $-498480.0 | 2021-12-31 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST- 361 Domestic Long/Short Equity Fund | SRNE | -3919.0 shares, $-13520.55 | 2022-01-31 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | SRNE | -3058.0 shares, $-10550.1 | 2022-01-31 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | SRNE | -518.0 shares, $-1206.94 | 2022-03-31 | N-PORT |